HUTCHMED Announces New Clinical Data Presentations on Cancer and Hematology Therapies at 2025 ESMO Asia and ASH Meetings

Reuters11-27

HUTCHMED Announces New Clinical Data Presentations on Cancer and Hematology Therapies at 2025 ESMO Asia and ASH Meetings

HUTCHMED (China) Ltd. has announced that new and updated data from several of its clinical studies will be presented at upcoming international conferences. These include the European Society for Medical Oncology (ESMO) Asia Congress 2025, set to take place from December 5-7, 2025 in Singapore, and the American Society of Hematology $(ASH)$ Annual Meeting, scheduled for December 6-9, 2025 in Orlando, USA. Notable presentations will feature results from a first-in-human study of the anti-CD47 monoclonal antibody HMPL-A83 in advanced solid tumors, the final analysis of long-term results from the ESLIM-01 Phase III study of sovleplenib in adults with chronic primary immune thrombocytopenia, and various studies on fruquintinib, surufatinib, and savolitinib in different cancer indications. The results are scheduled to be presented at these conferences and have not yet been disclosed.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HUTCHMED (China) Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9592796-en) on November 27, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2586993382?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-27 08:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2586993382","market":"us","top_or_hot":-1,"title":"HUTCHMED Announces New Clinical Data Presentations on Cancer and Hematology Therapies at 2025 ESMO Asia and ASH Meetings","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      HUTCHMED Announces New Clinical Data Presentations on Cancer and Hematology Therapies at 2025 ESMO Asia and ASH Meetings\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        HUTCHMED (China) Ltd. has announced that new and updated data from several of its clinical studies will be presented at upcoming international conferences. These include the European Society for Medical Oncology (ESMO) Asia Congress 2025, set to take place from December 5-7, 2025 in Singapore, and the American Society of Hematology <a href=\"https://laohu8.com/S/ASH\">$(ASH)$</a> Annual Meeting, scheduled for December 6-9, 2025 in Orlando, USA. Notable presentations will feature results from a first-in-human study of the anti-CD47 monoclonal antibody HMPL-A83 in advanced solid tumors, the final analysis of long-term results from the ESLIM-01 Phase III study of sovleplenib in adults with chronic primary immune thrombocytopenia, and various studies on fruquintinib, surufatinib, and savolitinib in different cancer indications. The results are scheduled to be presented at these conferences and have not yet been disclosed.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HUTCHMED (China) Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9592796-en) on November 27, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HUTCHMED Announces New Clinical Data Presentations on Cancer and Hematology Therapies at 2025 ESMO Asia and ASH Meetings</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHUTCHMED Announces New Clinical Data Presentations on Cancer and Hematology Therapies at 2025 ESMO Asia and ASH Meetings\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-27 08:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      HUTCHMED Announces New Clinical Data Presentations on Cancer and Hematology Therapies at 2025 ESMO Asia and ASH Meetings\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        HUTCHMED (China) Ltd. has announced that new and updated data from several of its clinical studies will be presented at upcoming international conferences. These include the European Society for Medical Oncology (ESMO) Asia Congress 2025, set to take place from December 5-7, 2025 in Singapore, and the American Society of Hematology <a href=\"https://laohu8.com/S/ASH\">$(ASH)$</a> Annual Meeting, scheduled for December 6-9, 2025 in Orlando, USA. Notable presentations will feature results from a first-in-human study of the anti-CD47 monoclonal antibody HMPL-A83 in advanced solid tumors, the final analysis of long-term results from the ESLIM-01 Phase III study of sovleplenib in adults with chronic primary immune thrombocytopenia, and various studies on fruquintinib, surufatinib, and savolitinib in different cancer indications. The results are scheduled to be presented at these conferences and have not yet been disclosed.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HUTCHMED (China) Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9592796-en) on November 27, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"00013","symbol_name":"和黄医药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251127:nNDL2vvF3b:1","article_id":"2586993382","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2586993382","pubTimestamp":1764201614,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"HUTCHMED  Ltd. has announced that new and updated data from several of its clinical studies will be presented at upcoming international conferences. These include the European Society for Medical Oncology  Asia Congress 2025, set to take place from December 5-7, 2025 in Singapore, and the American Society of Hematology  Annual Meeting, scheduled for December 6-9, 2025 in Orlando, USA. Notable presentations will feature results from a first-in-human study of the anti-CD47 monoclonal antibody HMPL-A83 in advanced solid tumors, the final analysis of long-term results from the ESLIM-01 Phase III study of sovleplenib in adults with chronic primary immune thrombocytopenia, and various studies on fruquintinib, surufatinib, and savolitinib in different cancer indications. The results are scheduled to be presented at these conferences and have not yet been disclosed.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to pr","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"00013":"和黄医药","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","NDAQ":"纳斯达克OMX交易所","BK1588":"回港中概股","BK1191":"制药","BK1587":"次新股","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","BK4585":"ETF&股票定投概念","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","BK4112":"金融交易所和数据","BK4588":"碎股","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC"},"translate_title":"和黄医药在2025年ESMO Asia和ASH会议上宣布癌症和血液学疗法的新临床数据演示","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NDAQ":0.9,"00013":0.9},"content_text":"HUTCHMED Announces New Clinical Data Presentations on Cancer and Hematology Therapies at 2025 ESMO Asia and ASH Meetings\n    \n\n        HUTCHMED (China) Ltd. has announced that new and updated data from several of its clinical studies will be presented at upcoming international conferences. These include the European Society for Medical Oncology (ESMO) Asia Congress 2025, set to take place from December 5-7, 2025 in Singapore, and the American Society of Hematology $(ASH)$ Annual Meeting, scheduled for December 6-9, 2025 in Orlando, USA. Notable presentations will feature results from a first-in-human study of the anti-CD47 monoclonal antibody HMPL-A83 in advanced solid tumors, the final analysis of long-term results from the ESLIM-01 Phase III study of sovleplenib in adults with chronic primary immune thrombocytopenia, and various studies on fruquintinib, surufatinib, and savolitinib in different cancer indications. The results are scheduled to be presented at these conferences and have not yet been disclosed.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HUTCHMED (China) Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9592796-en) on November 27, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2586993382","isCrawlerRequest":true}